ATE108661T1 - Behandlung von autoimmunen krankheiten mit immunoverstärkungssubstanzen. - Google Patents

Behandlung von autoimmunen krankheiten mit immunoverstärkungssubstanzen.

Info

Publication number
ATE108661T1
ATE108661T1 AT87104992T AT87104992T ATE108661T1 AT E108661 T1 ATE108661 T1 AT E108661T1 AT 87104992 T AT87104992 T AT 87104992T AT 87104992 T AT87104992 T AT 87104992T AT E108661 T1 ATE108661 T1 AT E108661T1
Authority
AT
Austria
Prior art keywords
treatment
autoimmune diseases
immune enhancement
immune
amplifiers
Prior art date
Application number
AT87104992T
Other languages
English (en)
Inventor
A Arthur Dr M D Gottlieb
Suite
Original Assignee
Imreg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imreg Inc filed Critical Imreg Inc
Application granted granted Critical
Publication of ATE108661T1 publication Critical patent/ATE108661T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT87104992T 1986-04-04 1987-04-03 Behandlung von autoimmunen krankheiten mit immunoverstärkungssubstanzen. ATE108661T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/848,210 US4710380A (en) 1986-04-04 1986-04-04 Treatment of autoimmune disorders with immunoamplifiers

Publications (1)

Publication Number Publication Date
ATE108661T1 true ATE108661T1 (de) 1994-08-15

Family

ID=25302666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87104992T ATE108661T1 (de) 1986-04-04 1987-04-03 Behandlung von autoimmunen krankheiten mit immunoverstärkungssubstanzen.

Country Status (5)

Country Link
US (1) US4710380A (de)
EP (1) EP0240033B1 (de)
AT (1) ATE108661T1 (de)
CA (1) CA1284948C (de)
DE (1) DE3750235T2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766920A (en) * 1982-08-11 1998-06-16 Cellcor, Inc. Ex vivo activation of immune cells
CA1286989C (en) 1985-12-26 1991-07-30 A. Arthur Gottlieb Immunoamplifiers and related compositions
US4874608A (en) * 1987-04-27 1989-10-17 Imreg, Inc. Therapeutic method for treating malignancies
US6136788A (en) * 1987-12-30 2000-10-24 Cytran, Inc. Pharmaceutical preparation for the therapy of immune deficiency conditions
AU616236B2 (en) * 1987-12-30 1991-10-24 Cytran Ltd. Pharmaceutical preparation for treating immunodeficiency conditions
US5814611A (en) * 1988-12-14 1998-09-29 Cytoven J.V. Pharmaceutical for the therapy of immune deficiency conditions
US5055296A (en) * 1988-08-04 1991-10-08 Wagle Sudhakar S Method of treating chronic fatigue syndrome
US5334395A (en) * 1988-08-04 1994-08-02 Kremers-Urban Company Method of treating an epstein-barr viral infection
US5284664A (en) * 1988-08-04 1994-02-08 Kremers-Urban Company Method of treating the symptoms of Alzheimer's disease
US5316775A (en) * 1988-08-04 1994-05-31 Kremers-Urban Company Method of treating hepatitis B infection
US5013546A (en) * 1988-08-23 1991-05-07 Imreg, Inc. Methods for modulating antibody production in treating patients with AIDS, ARC and other diseases
US7008790B1 (en) * 1993-08-12 2006-03-07 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US5728385A (en) 1993-08-12 1998-03-17 Classen Immunotherapies, Inc. Method and composition for an early vaccine to protect against both common infectious diseases and chronic immune mediated disorders or their sequelae
US7632818B2 (en) * 2003-03-20 2009-12-15 Gottlieb Marise S Method for treating conditions associated with the Metabolic Syndrome (Syndrome X)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468379A (en) * 1982-05-06 1984-08-28 Endeavor Corp. Leukocyte extracts for affecting the immune system
US4616079A (en) * 1984-08-24 1986-10-07 Imreg, Inc. Immunoamplifiers and processes for the extraction thereof

Also Published As

Publication number Publication date
DE3750235T2 (de) 1994-10-27
EP0240033B1 (de) 1994-07-20
EP0240033A3 (en) 1990-01-17
US4710380A (en) 1987-12-01
DE3750235D1 (de) 1994-08-25
EP0240033A2 (de) 1987-10-07
CA1284948C (en) 1991-06-18

Similar Documents

Publication Publication Date Title
DE3750235D1 (de) Behandlung von autoimmunen Krankheiten mit Immunoverstärkungssubstanzen.
ATE72991T1 (de) Nasale verabreichung von arzneimitteln.
ES2137948T3 (es) Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina.
BG60253B1 (bg) Човешки тъканен плазминогенен активатор
NO821832L (no) Fremgangsmaate for fremstilling av allergenholdige kapsler
DE3588023D1 (de) Mittel zur Behandlung von Herzerkrankungen.
DE69731540D1 (de) Behandlung von diarrhoe
NO991784L (no) Purin-L-nukleosider, analoger og anvendelser derav
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
FR2362834A1 (fr) Nouveaux derives 6-hemicetal ou 6-ceto de prostaglandine, leur procede de preparation et medicament les contenant
IS1565B (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
FI874163A7 (fi) Katekolijohdannaiset sekä niitä sisältävät keskushermoston taantumasairauksia ehkäisevät ja parantavat valmisteet.
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
EP0270690A4 (de) Arzneimittel zur behandlung und prophylaxe von leber- und nierenkrankheiten.
DE3684755D1 (de) Behandlung von tieren mit il-2, zubereitungen dafuer und ihre herstellung.
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
DK607885A (da) Medikamentpraeparater med formindsket giftighed
OA07684A (fr) Nouveaux acides flavone-carboxylique-4, leur méthode de préparation et leur application thérapeutique.
BG93298A (bg) Имуностимулиращи 6-арил-5,6-дихидроимидазо(2,1-в)тиазолови производни
DE60029948D1 (de) Verbesserte methode zur behandlung von säugetieren mit geändertes säugetierblut
RU94022481A (ru) Способ определения иммуногенной активности биоактивных соединений и состав для его осуществления
Selvini Palazzoli et al. Snares in family therapy.
IL105498A0 (en) Pharmaceutical composition containing ribonucleotide polymerase
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
DE3775854D1 (de) Arzneimittel zur therapie von durch funktionelle und organische basen verursachten gehirnkrankheiten.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties